Please check your internet connection and try again.
## Piperacillin/Tazobactam (Zosyn)
### Overview
Piperacillin/tazobactam is a combination penicillin antibiotic and beta-lactamase inhibitor, effective against a broad spectrum of Gram-positive, Gram-negative, and anaerobic bacteria.
### Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Empirical treatment of febrile neutropenia (often in combination with an aminoglycoside)
### Adult Dosing
* **Standard Dose:** 3.375 g (3 g piperacillin / 0.375 g tazobactam) or 4.5 g (4 g piperacillin / 0.5 g tazobactam) intravenously every 6 hours.
* **Maximum Dose:** Not to exceed 4.5 g every 6 hours.
* Dosing frequency and duration are dependent on the indication, severity of infection, and clinical response. For severe infections or in critically ill patients, extended infusion (e.g., 4 hours) or continuous infusion may be considered, potentially allowing for higher total daily doses. Specific protocols should be followed.
### Pediatric Dosing
* **Children < 2 months:** Dosing is not well-established and should be based on gestational and chronological age, weight, and severity of infection. Consult specialized pediatric guidelines.
* **Children ≥ 2 months:**
* **Dosing based on piperacillin component:** 80 mg/kg to 120 mg/kg (piperacillin) per dose, administered intravenously every 6 or 8 hours.
* **Tazobactam component:** 10 mg/kg to 15 mg/kg (tazobactam) per dose, administered intravenously every 6 or 8 hours.
* **Maximum dose:** Does not exceed the adult maximum of 4 g piperacillin per dose.
* Specific indications (e.g., febrile neutropenia) may require different dosing strategies or combinations. Consult pediatric infectious disease specialists or specific institutional protocols.
### Dose Adjustments
* **Renal Impairment:**
* CrCl ≥ 40 mL/min: No adjustment needed.
* CrCl 20-39 mL/min: Administer the standard dose every 8 hours.
* CrCl < 20 mL/min: Administer the standard dose every 12 hours.
* For intermittent infusions, doses should be administered over 30 minutes. For continuous infusions, the rate may need adjustment.
* **Hepatic Impairment:** No dose adjustment is generally required.
### Contraindications
* Known severe hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant penicillins, or any component of the formulation.
* History of immediate or severe allergic reaction to beta-lactam antibiotics.
### Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever, phlebitis.
* **Serious:** Hypersensitivity reactions (including anaphylaxis), Clostridioides difficile-associated diarrhea (CDAD), seizure (especially with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes, interstitial nephritis.
### Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin. Closely monitor INR.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels.
* **Live bacterial vaccines:** Reduced efficacy of vaccines.
### Monitoring
* **Renal function:** Essential for dose adjustment in renal impairment.
* **Liver function tests:** Monitor for elevations, particularly with prolonged therapy.
* **Hematologic parameters:** Monitor for neutropenia, thrombocytopenia, and eosinophilia, especially with prolonged or high-dose therapy.
* **Signs and symptoms of infection:** Clinical response, fever, white blood cell count.
* **Electrolytes:** Especially potassium, due to the potential for hypokalemia with high doses or prolonged infusions.
* **Signs and symptoms of hypersensitivity reactions.**
* **Stool for C. difficile:** If diarrhea develops.
### Clinical Pearls
* Piperacillin/tazobactam is a broad-spectrum agent often used empirically for serious infections, including those caused by resistant organisms.
* Tazobactam extends the spectrum of activity by inhibiting beta-lactamases.
* Extended or continuous infusions may improve efficacy and reduce the development of resistance by maintaining higher drug concentrations above the minimum inhibitory concentration (MIC).
* Ensure adequate hydration and electrolyte balance, particularly in patients receiving large doses or continuous infusions.
* Discontinuation of piperacillin/tazobactam and substitution with a narrower-spectrum agent should be considered once culture and susceptibility results are available.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant institutional guidelines before administering any medication. Verify all doses and recommendations with your institution's formulary and protocols.
